The M Blog

Mass Tort Updates from the Frontlines

Real-time litigation alerts, FDA actions, MDL milestones, and industry analysis.

No pay-to-play coverage. No sponsored posts. Just the active torts MTAA is watching, working on, or running campaigns for — published as the news breaks.

What the M Blog covers

The M Blog is Mass Tort Ad Agency's working log of the plaintiff-side mass tort landscape, written by the people running the campaigns. We post when an FDA action changes a tort's trajectory, when an MDL hits a procedural milestone (Daubert ruling, bellwether result, settlement framework), when a new product safety signal appears in FAERS or peer-reviewed literature, and when a tort we're advertising heats up enough to be worth a public note.

Topics covered regularly: mass torts we track and write about (Dupixent, Paragard IUD, 1,4-Dioxane, EtO sterilization, Discord and Roblox child safety, hair relaxer cancer, talc, Video Game Addiction, social media addiction, and others as they develop); MDL operational analysis (claimant inventory dynamics, common benefit fund mechanics, settlement-yield math); plaintiff advertising operations (cost-per-signed-retainer benchmarks, qualification standards, intake throughput); and industry context (firm financing, litigation funder dynamics, bar-disciplinary cases against case-buying operations).

No pay-to-play coverage. No sponsored posts. No affiliate links. If MTAA writes about a tort, it's because the tort matters to plaintiff firms making real decisions about where to deploy capital and intake capacity. New posts ship weekly. The full archive is below; filter by category to narrow in on the area you care about.